Neuroscience - Press Kit & Media Assets
Access comprehensive materials for Driving the next chapter of neuroscience, including branding assets, press releases, reports, and media resources.
At Teva, we focus on addressing some of the most complex and urgent challenges in neuroscience today.
Driving the next chapter of neuroscience
Our commitment to investigating neurological conditions stretches over 30 years, when we brought our first treatments to market. Driven by our dedication to rigorous scientific inquiry, we concentrate our research on areas with significant unmet needs – including mental health conditions, movement disorders, and migraine, with dedicated research across areas such as schizophrenia, Huntington’s disease chorea, tardive dyskinesia, and related neurological conditions.
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
